Skip to main content

Table 6 Adjusted HRs and 95% CIs for time to serious infection (n = 21,832)

From: Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study

Parameter Adjusted HR 95% CI
Drug therapy
 Non-TNF biologic ± DMARDs Reference
 DMARDs 0.80 0.62–1.03
 TNFi ± DMARDs 1.14 0.95–1.37
 Tofacitinib ± DMARDs 1.54 0.93–2.56
Current use of methotrexatea 1.19 1.04–1.37
Previous use of biologicsa 1.32 1.12–1.57
Previous use of other DMARDsa 1.04 0.86–1.27
Sex (female) 1.02 0.87–1.18
Age 1.04 1.03–1.04
Year of cohort entry
 2011 Reference
 2012 1.10 0.92–1.31
 2013 0.85 0.66–1.08
 2014 0.97 0.70–1.35
Oral glucocorticoid use one year prior to cohort entry
 No use Reference
 Use of ≤ 7.5 mg/day of prednisone equivalent dose 1.23 1.05–1.44
 Use of > 7.5 mg/day of prednisone equivalent dose 1.36 1.00–1.84
Current use of oral glucocorticoida
 No use Reference
 Use of ≤ 7.5 mg/day of prednisone equivalent dose 1.90 1.64–2.20
 Use of > 7.5 mg/day of prednisone equivalent dose 2.83 1.37–5.83
Nonsteroidal anti-inflammatory drugs use 1 year prior to cohort entry 0.93 0.81–1.06
Selective COX-2 inhibitors use 1 year prior to cohort entry 1.13 0.95–1.35
Charlson comorbidity index 1 year prior to cohort entry 1.72 1.49–1.99
Infection related hospitalization 1 year prior to cohort entry 2.19 1.68–2.86
Number of emergency department visits 1 year prior to cohort entry 1.04 1.01–1.06
Number of physician visits 1 year prior to cohort entry 1.01 1.00–1.01
Number of rheumatology visits 1 year prior to cohort entry 1.00 0.99–1.02
Number of hospitalizations 1 year prior to cohort entry 1.33 1.24–1.43
  1. DMARDs Disease-modifying antirheumatic drug, TNFi Tumor necrosis factor inhibitors
  2. aTime-varying covariates